Edgewise Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 100.16 million compared to USD 67.64 million a year ago. Basic loss per share from continuing operations was USD 1.57 compared to USD 1.26 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.44 USD | -0.23% | -17.85% | +59.41% |
05-10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
05-09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.41% | 1.63B | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023